文献速递临床免疫质量管理与危急值临床生化

芬太尼检测利用不足掩盖印第安纳州常规尿液药物筛查中的大量芬太尼暴露

Underutilization of fentanyl testing masks substantial fentanyl exposure in routine urine drug screens in Indiana.
PubMed 文献 · Clin Chim Acta · 2026-03-11

本研究评估印第安纳州2052份连续尿液标本中芬太尼筛查的利用率和阳性率,以及芬太尼阳性标本中赛拉嗪的共存情况,并与州卫生部门芬太尼过量数据关联。仅1.6%的标本开具了芬太尼检测,免疫分析筛查显示13%推定阳性,其中97%经LC-MS/MS确认阳性,48份标本检出赛拉嗪;芬太尼筛查阳性标本来自过量死亡较高的地区。

要点

  • 常规尿液药物筛查中芬太尼检测开具率极低,仅1.6%。
  • 免疫分析筛查推定阳性率13%,LC-MS/MS确认阳性率97%。
  • 芬太尼阳性标本中检出赛拉嗪,且阳性标本来源地区过量死亡更高。

核心结论

  • 免疫分析仍是尿液药物筛查的核心,但现有检测 panel 常滞后于新兴药物趋势。
  • 芬太尼检测利用不足,尿液药物筛查阴性结果可能并不代表标本不含药物。

研究设计与样本

  • 研究纳入2052份连续提交尿液药物筛查的尿液标本。
  • 其中1864份标本进行芬太尼免疫分析筛查,188份因体积不足未检测。
  • 推定阳性标本用LC-MS/MS分析芬太尼、去甲芬太尼、4-ANPP和赛拉嗪。
  • 基于ZIP码信息将芬太尼推定阳性数据与州过量数据关联。

主要发现

  • 提交尿液药物筛查的标本中,1.6%(n=33)包含芬太尼检测医嘱。
  • 其余标本免疫分析筛查得出13%(n=233)推定阳性,其中97%(n=226)确认阳性。
  • 在48份标本中同时检出赛拉嗪。
  • 芬太尼筛查阳性标本来源于过量死亡较高的地区。

关键数值与推荐

  • 芬太尼检测医嘱率:1.6%(n=33/2052)。
  • 免疫分析推定阳性率:13%(n=233/1864)。
  • 推定阳性确认阳性率:97%(n=226/233)。
  • 赛拉嗪检出标本数:48份。

临床怎么用

  • 临床应提高对芬太尼检测的利用,避免因未开具检测而漏检。
  • 尿液药物筛查阴性不能排除芬太尼等新兴药物暴露。
  • 应根据新兴药物趋势和检测方法可及性更新尿液药物筛查 panel。

局限性

  • 188份标本因体积不足未进行芬太尼免疫分析筛查。
  • 研究基于ZIP码信息关联州过量数据,可能存在生态学偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Timely and locally relevant drug testing is helpful for overdose assessment; however, immunoassay (IA)-based urine drug screens (UDS) often fail to detect emerging substances. This study assesses fentanyl screen utilization and positivity rate, concurrent xylazine presence in fentanyl positive specimens, and compares this information with the fentanyl overdose data from the Indiana Department of Health. METHODS: Consecutive urine specimens (n = 2052) submitted for UDS were screened by fentanyl immunoassays (total, n = 1864; n = 188 had insufficient volume). Presumptive positive specimens were analyzed by LC-MS/MS for fentanyl, norfentanyl, 4-anilino-N-phenethylpiperidine (4-ANPP), and xylazine. Based on ZIP code information, fentanyl presumptive positive data was correlated with state overdose data. RESULTS: Of the specimens submitted for UDS, 1.6% (n = 33) included a fentanyl order. IA screening of the remainder resulted in 13% (n = 233) presumptive positivity, of which 97% (n = 226) confirmed positive. Xylazine was also detected in 48 specimens. Fentanyl screen positive specimens originated from areas with higher overdose deaths. CONCLUSIONS: IAs remain central to UDS but available panels often lag behind emerging drug trends. As fentanyl drives rising overdose rates, rapid detection is critical. This study highlights increased fentanyl detection in a clinical UDS cohort across Indiana and emphasizes that UDS negative results may not indicate drug-free specimens, therefore, UDS panels should be updated based on emerging trends and assay availability.

来源:Clin Chim Acta,查看原文。版权归原作者所有。

引用

  1. Olaniyan H, Beckman J, Crosby E, et al. Underutilization of fentanyl testing masks substantial fentanyl exposure in routine urine drug screens in Indiana. Clin Chim Acta. 2026. PMID: 41825758. doi:10.1016/j.cca.2026.120948

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。